Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

@article{Kirchheiner2003BupropionA4,
  title={Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.},
  author={Julia Kirchheiner and Christiane Klein and Ingolf Meineke and Johanna Sasse and Ulrich M. Zanger and Thomas E M{\"u}rdter and Ivar Roots and J{\"u}rgen Brockm{\"o}ller},
  journal={Pharmacogenetics},
  year={2003},
  volume={13},
  pages={619-626}
}
Bupropion is applied in depression and smoking cessation. Genetic polymorphisms in cytochrome P450 2B6 (CYP2B6) may cause variability in bupropion pharmacokinetics since hydroxylation is known to be mediated by CYP2B6. Bupropion may be a probe drug for CYP2B6 activity in humans. Bupropion pharmacokinetics were studied after a single oral dose of 150 mg in 121 healthy male volunteers. The amino acid polymorphisms R22C, Q172H, S259R, K262R and R487C were analysed by polymerase chain reaction and… Expand
Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes
TLDR
This study reports the first in vivo evidence that reduced CYP2C19 activity significantly increases the steady-state exposure to bupropion and its reductive metabolites threohydrobupropion and erythrohydrob upropion. Expand
Gene Variants in CYP 2 C 19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes s
Bupropion is used clinically to treat depression and to promote smoking cessation. It is metabolized by CYP2B6 to its activemetabolite hydroxybupropion, yet alterations in CYP2B6 activity have littleExpand
Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status
TLDR
The case of a 28-year-old male Caucasian outpatient suffering from major depressive disorder who did not respond to a treatment with bupropion illustrates the clinical relevance of therapeutic drug monitoring in combination with pharmacogenetics diagnostics for a personalized treatment approach. Expand
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.
TLDR
Because the principal metabolites of bupropion possess similar pharmacological activity to the parent compound, dosage recommendations for patients with renal impairment cannot be given. Expand
HPLC assay for bupropion and its major metabolites in human plasma.
TLDR
This HPLC assay is more sensitive than currently published methods using HPLC with UV detection for the simultaneous quantitation of bupropion and metabolites and can be used for assessing CYP2B6 activity in vivo following a single dose of buPropion. Expand
Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes
TLDR
Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of buPropion as an antidepressant or smoking cessation therapy, and for the use of bupropions as an in vivo phenotypic probe for CYP2B6 activity. Expand
Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation
TLDR
Baicalin significantly induced CYP2B6-catalyzed bupropion hydroxylation, and the effects of baicalin on other CYP 2B6 substrate drugs deserve further investigation. Expand
Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers
TLDR
The prediction of steady-state pharmacokinetics demonstrated differential stereospecific accumulation and elimination of bupropion effect and DDI risk with CYP2D6 at steady state, which may explain observed stereoselective differences. Expand
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
TLDR
The results of this study indicate that interindividual variability in bupropion hydroxylation is a consequence of interactions between environmental and genetic influences on CYP2B6 gene function. Expand
CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial
TLDR
The data suggest that smokers with the CYP2B6*6 genotype have a higher liability to relapse on placebo and that they may be good candidates for bupropion treatment for smoking cessation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
TLDR
Bupropion hydroxylation is mediated almost exclusively by CYP2B6 and can serve as an index reaction reflecting activity of this isoform and suggest a low inhibitory potency versus CYP 2D6, the clinical importance of which is not established. Expand
Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers
TLDR
The absence of pharmacokinetic differences indicates that dosage adjustments are not necessary when bupropion is prescribed to male and female cigarette smokers. Expand
Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
TLDR
Results demonstrate selectivity of BUP hydroxylation for CYP2B6 at 500 microM BUP, thereby validating its use as a diagnostic in vitro marker of CYP 2B6 catalytic activity. Expand
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
TLDR
It is demonstrated that the polymorphic CYP2B6 is a major enzyme in the bioactivation of CPA and showed much higher in vitro intrinsic clearance than previously observed in recombinant CYP 2C19 and CyP2C9 variants in yeast expression system. Expand
Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose
TLDR
Because of the substantial presence of these metabolites in systemic circulation, further studies are recommended to understand further their roles in the clinical profile of this new antidepressant. Expand
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
TLDR
Frequency of the two CYP2C9 variants in Turkish subjects was in a similar range as in other Caucasian populations, and a significant proportion of the interindividual variability in phenytoin trough levels is explained by the genotypes. Expand
Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.
TLDR
It is suggested that CYP3A4 does not significantly catalyze BUP hydroxylation, and this results complement recent data supporting selectivity of B UP hydroxymation for CYP2B6 at 500 microM BUP. Expand
Single‐Dose Pharmacokinetics of Bupropion in Adolescents: Effects of Smoking Status and Gender
TLDR
In conclusion, smoking status does not affect the single‐dose pharmacokinetics of bupropion SR in adolescents, however, females differ from males in several potentially important PK parameters for buPropion and its major metabolite, hydroxybupropion. Expand
Metabolism and kinetics of bupropion.
: Studies of bupropion in rats, dogs, and normal volunteers showed that bupropion was rapidly and completely absorbed, widely distributed in tissues, and metabolized extensively prior to itsExpand
Functional characterization of cytochrome P450 2B6 allelic variants.
TLDR
Results may mean that Lys262 in combination with other amino acid residues such as Gln172 and Arg487 is associated with the CYP2B6 function and that the genetic polymorphism of CYP 2B6 leads to interindividual differences in xenobiotic metabolism. Expand
...
1
2
3
4
...